PROM1 and head and neck squamous cell carcinoma: In recent years, a toxin-based system to simultaneously target CD133 and EpCAM in the same cell was developed in different carcinoma models, including inflammatory breast carcinoma, showing a potent inhibition of proliferation in vitro and the regression of HNSCC (Head and neck squamous cell carcinoma) in vivo [15].